Core Points - Weigao Blood Purification (603014.SH) is planning to acquire 100% equity of Shandong Weigao Purui Pharmaceutical Packaging Co., Ltd. through a share issuance, which will make Weigao Purui a wholly-owned subsidiary of the company [1] - The transaction is expected to constitute a major asset restructuring and related party transaction, but will not lead to a change in the actual controller of the company and does not constitute a restructuring listing [1] - The company has signed a Cooperation Intent Agreement with the transaction parties, outlining the preliminary intentions for the acquisition [1] Summary by Sections - Transaction Details - The acquisition is still in the planning stage, and the parties have not yet signed a formal transaction agreement [2] - The specific transaction plan is under negotiation and remains uncertain [2] - Regulatory Approval - The transaction requires approval from the company's board of directors, shareholders, and relevant regulatory authorities before it can be officially implemented [2] - There is uncertainty regarding whether the necessary approvals will be obtained and the timeline for such approvals [2] - Stock Suspension - To protect investor interests and ensure fair information disclosure, the company has applied for a trading suspension starting from October 20, 2025, for a period not exceeding 10 trading days [1]
威高血净下周一停牌 拟发行股份购买威高普瑞100%股权